Enovis Corporation (NYSE:ENOV) Given Average Rating of “Moderate Buy” by Analysts

Posted by Francis Steltz on May 15th, 2026

Enovis Corporation (NYSE:ENOV – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $45.1667.

ENOV has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a report on Sunday, May 10th. Zacks Research upgraded shares of Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. Needham & Company LLC raised their target price on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Finally, William Blair started coverage on shares of Enovis in a research note on Friday, April 17th. They issued an “outperform” rating on the stock.

Get Our Latest Research Report on ENOV

Insider Activity

In other news, insider Oliver Engert bought 1,000 shares of Enovis stock in a transaction dated Friday, February 27th. The shares were purchased at an average cost of $25.50 per share, with a total value of $25,500.00. Following the completion of the acquisition, the insider owned 43,640 shares of the company’s stock, valued at $1,112,820. This trade represents a 2.35% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders bought 5,000 shares of company stock valued at $121,983 over the last quarter. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Several institutional investors have recently added to or reduced their stakes in ENOV. Gabelli Funds LLC raised its holdings in shares of Enovis by 26.1% during the 1st quarter. Gabelli Funds LLC now owns 11,049 shares of the company’s stock worth $251,000 after acquiring an additional 2,287 shares in the last quarter. Gamco Investors INC. ET AL grew its holdings in shares of Enovis by 27.1% in the first quarter. Gamco Investors INC. ET AL now owns 14,067 shares of the company’s stock valued at $320,000 after purchasing an additional 3,001 shares in the last quarter. Paradigm Capital Management Inc. NY increased its position in Enovis by 70.2% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after purchasing an additional 732,917 shares during the last quarter. Caxton Associates LLP increased its position in Enovis by 30.4% in the first quarter. Caxton Associates LLP now owns 12,884 shares of the company’s stock worth $293,000 after purchasing an additional 3,007 shares during the last quarter. Finally, Sei Investments Co. raised its stake in Enovis by 37.1% during the first quarter. Sei Investments Co. now owns 164,253 shares of the company’s stock valued at $3,737,000 after purchasing an additional 44,474 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Trading Up 1.6%

Shares of ENOV stock opened at $26.12 on Friday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The stock has a fifty day simple moving average of $23.96 and a two-hundred day simple moving average of $25.56. The firm has a market capitalization of $1.50 billion, a PE ratio of -1.31 and a beta of 1.41. Enovis has a 52-week low of $21.00 and a 52-week high of $36.82.

Enovis (NYSE:ENOV – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.82 by $0.07. The business had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The business’s revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts predict that Enovis will post 3.65 EPS for the current fiscal year.

About Enovis

(Get Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.